GPT

Across TCGA pan-cancer cohorts, GPT mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GPT data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GPT mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GPT expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where GPT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.880	0.253	<.001	77	view →
LUAD	DFS	Median	III,IV	0.560	0.923	.002	62	view →
PDAC	DFS	Median	All	0.585	0.322	<.001	27	view →
LSCC	DFS	Tertile	All	0.443	0.841	.006	13	view →
GBM	OS	Median	All	0.430	0.617	.005	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GPT–CCRCC (DFS)

Open the CCRCC breakdown →